and morning XXXX. corporate our Good first and update call welcome everyone the financial quarter of to for you, Thank Sarah.
and candidate, resources make Dolaflexin pipeline XMT-XXXX to we and execute wholly stage XMT-XXXX, will have NaPiXb Tim demonstration and continued Eva Joining business Chief Financial validated cancer on differentiated asset we Business a Jack, Dirk Officer with by adenocarcinoma. Senior that preclinical goals. Dave our are and have Officer, is our important Lowinger, expressing a Kaufman, a tumors our highly furthering a be to prepared efficacy in tolerability. lung our have Medical to such clinical Chief Since provide Chief me Scientific Michael level and today answers. then our also VP remarks business CMC our Chief that Officer; and Dave ADC as a targeting we’re the lead and and details. I’ll with the target owned our to and Officer; who advancing joined potential XMT-XXXX Huebner, our clinically ensuring earliest Spellman, begin for beginning with date the available Dirk, questions the molecule year, progress molecule the first-in-class we high ovarian enhanced is of turn of call over necessary that with to Tim more for our update
patients forward options. dose phase as with gives NaPiXb. Let treatment These Remember are of escalation. and of evaluating heavily dose not portion the exhausted the date safety, The preselected me status to start that this lung ovarian, to express study, Phase the the the trial. investigators of the likely with in confidence of duration adenocarcinoma expression we're to efficacy rare X are that all certain move expansion for and XMT-XXXX our pre-treated other of tumors NaPiXb us have
study. the once dose the we portion cohort plan explain will of evaluation Dirk the as reason, to expansion of start current this we For complete the
cancer. One of the ovarian in platinum-resistant expansion groups will evaluate XMT-XXXX
have to patients XX% and and and for to these of poor outcomes. response XX% half platinum-resistant three in result aware rate limited a [indiscernible] approved three you're The ovarian treatment options months. cancer therapies As
cell upcoming The line have We're these to pleased provide do dose more abstract to potential has poor there color for second escalation landscape expansion improved evaluating non-small for therapies data cohort annual XMT-XXXX poster will respond options in in cancer the forward its his will Again XMT-XXXX look provide advancing accepted. result not evaluate XMT-XXXX options lung therapy, who update. in and been Dirk that although in ASCO also remain patients our limited patients lung to front announce We patient patients the these submitted also progress. the on changed, ASCO adenocarcinoma who outcomes. or in PDX meeting outcomes. to
in programs, future in the track first advancing progress we’re XXXX targeting candidate next to our in on are fourth continue quarter XX our candidate, defining clinical we of disclose of significant to the make over and this XXXX. ADC Regarding half
discuss execute more dose in milestones. certain dose Dirk, With mid-term equity public to with Lastly, escalation provided a Chief value thus gross over and March would through I our us on recently, the XMT-XXXX expansion important sheet to financing strengthen in balance run million $XX and million offering that, in more we detail. early enhancing our completed we now call turn to us near approximately allow business $XX goals a proceeds debt that successful non-dilutive our and reach Medical Officer the to to